Sintilimab plus bevacizumab for untreated rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—for people with rectal cancer that hasn't been treated yet. It aims to see if this combination can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rectal cancer that has been confirmed by a biopsy (tissue sample).
- You cannot have received any prior treatment for your rectal cancer (except for people with Lynch syndrome, who may have had no treatment for this specific cancer).
- Your cancer must be at a certain stage (T1-3bN1-2 or T3aN0 or T3bN0) and not involve nearby muscles or blood vessels, as seen on an MRI.
- You need to be in generally good health with adequate organ function (like blood counts, liver and kidney function) and able to perform daily activities (ECOG score 0-1).
- You cannot have a history of certain other cancers, active autoimmune diseases, uncontrolled infections, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests whether giving a combination of chemotherapy, radiation, and two newer drugs (an immunotherapy and an anti-angiogenesis drug) before surgery can improve outcomes for people with locally advanced rectal cancer. If you qualify, you would receive this treatment for a few months, and then have surgery.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This Phase 2 trial studies whether adding sintilimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with locally advanced rectal cancer. It’s aimed at tumors with certain immune “signature” scores and specific cancer stage features.
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
This trial studies a combination of three drugs — an immunotherapy (sintilimab), a blood vessel growth blocker (bevacizumab), and a chemotherapy helper (decitabine) — for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer when standard options have failed.
Hear when a new Rcctal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.